盐酸替罗非班氯化钠注射液与心血管介入治疗急性心肌梗死患者临床效果

目的观察盐酸替罗非班氯化钠注射液(欣维宁)应用于急性心肌梗死(AMI)患者介入治疗(PCI)的临床效果及安全性。方法选取72例AMI患者并按入院顺序随机分为两组,36例患者采用盐酸替罗非班氯化钠注射液与心血管PCI治疗作为观察组,36例患者采用常规PCI治疗作为对照组,比较两组患者PCI术后梗死区域血管TIMI分级、术后4周内病死、血运重建、难治性心肌缺血及恶性心律失常等主要心血管不良事件的发生情况及不良反应发生情况。结果术后观察组TIMI分级3级者为33例(91.67%),明显高于对照组的26例(72.22%,χ2=4.60,P0.05)。观察组术后4周内主要心血管不良事件发生率为8.33%,明显低于对照组的27.28%(χ2=4.60,P0.05)。两组患者不良反应主要表现为皮肤黏膜出血或血管出血等,均无严重不良反应发生,观察组4例(11.12%)出血,对照组2例(5.55%)出血,两组患者不良反应发生率差异无统计学意义(χ2=0.73,P0.05)。结论盐酸替罗非班氯化钠注射液可有效恢复梗死区域血管血流,降低PCI术后主要不良心血管事件的发生,不良反应轻微。

Clinical effect of tirofiban hydrochloride sodium chloride injection with cardiovascular intervention in the treatment of patients with acute myocardial infarction

Objective To observe the clinical efficacy and safety of tirofiban hydrochloride and sodium chloride injection （Tirofiban） used in patients with acute myocardial infarction （AMI） treated by PCI. Methods A total of 72 patients with AMI were randomly divided into two groups according to the order of admission, 36 patients treated with sodium chloride with tirofiban hydrochloride injection, and cardiovascular PCI were as the observation group, and 36 patients with conventional PCI treatment were as control group. After PCI infarction the regional vascular TIMI grading, deaths after 4 weeks, revaseularization, four major adverse cardiovascular events like refractory myocardial ischemia and malignant arrhythmias, and the incidence of adverse reactions were observed and compared between the two groups. Results Postoperative TIMI grade 3 occurred in 33 patients （91.67%） of observation group, which was markedly higher than 26 cases in the control group （72.22% ,χ^2 =4.60,P 〈0.05）. Major cardiovascular adverse events after 4 weeks in the observation group was 8.33% , which was significantly lower than that the control group （ 27.28% ,χ^2 = 4.60,P 〈 0.05 ）. Adverse reactions manifested in 2 groups were skin and mucous membrane bleeding or blood vessels bleeding; there were no serious adverse reactions; bleeding was observed in 4 patients in observation group（ l 1.12% ） and in 2 cases of the control group （5.55%） ; There was no significant difference in the incidence of adverse reactions of two groups of patients （χ^2 = 0.73,P 〉 0.05 ）. Conclusion Sodium chloride tirofiban hydrochloride injection can effectively restore infarction regional blood flow, reduce the incidence of major adverse cardiovascular events after PCI, and the adverse reactions are mild.